Inventiva SACA

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

23 Mar 2023 17:00:00 By Nasdaq GlobeNewswire

Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

14 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

30 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023

26 Jan 2023 02:00:00 By Nasdaq GlobeNewswire

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

04 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022

03 Jan 2023 02:35:00 By Nasdaq GlobeNewswire

Combined General Meeting of January 25, 2023 - Availability of the preparatory documents

03 Jan 2023 02:30:00 By Nasdaq GlobeNewswire

Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

12 Dec 2022 02:30:00 By Nasdaq GlobeNewswire

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

28 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Inventiva announces a new Director of the Board of Directors

21 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Inventiva reports 2022 Third Quarter Financial Information¹

10 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Inventiva provides an update on the development of cedirogant by AbbVie

31 Oct 2022 03:00:00 By Nasdaq GlobeNewswire

Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

21 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

Inventiva reports its 2022 first-half financial results and provides a corporate update

22 Sep 2022 02:30:02 By Nasdaq GlobeNewswire

Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China

21 Sep 2022 16:40:00 By Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

07 Sep 2022 16:00:00 By Nasdaq GlobeNewswire

Inventiva Reports 2022 First-Half Financial Information¹

28 Jul 2022 16:00:00 By Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

21 Jul 2022 12:00:00 By Nasdaq GlobeNewswire

Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

07 Jul 2022 16:00:00 By Nasdaq GlobeNewswire

Update on Inventiva's cash position and on the finance documentation with the European Investment Bank

04 Jul 2022 12:45:00 By Nasdaq GlobeNewswire